Receptor tyrosine kinases have served as pharmacological targets in cancer treatment due to their frequent dysregulations, including gene amplifications, overexpression, and activating mutations, which promote tumor development, progression, and metastasis. This evidence concerns the gene NTRK1 and neoplasm.